Tekla Capital Management’s Accelerate Diagnostics AXDX Stock Holding History

Tekla Capital Management’s Portfolio AXDX Stock Details AXDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q4	–	Sell	-15,000	Closed	-$3.37M	–	161
2017 Q3	$3.37M	Buy	15,000 +5,000	+50%	+$1.23M	0.12%	100
2017 Q2	$2.73M	Hold	10,000	–	–	0.1%	104
2017 Q1	$2.42M	Sell	10,000 -2,000	-17%	-$457K	0.09%	104
2016 Q4	$2.49M	Hold	12,000	–	–	0.11%	97
2016 Q3	$3.27M	Sell	12,000 -14,463	-55%	-$3.2M	0.13%	103
2016 Q2	$3.81M	Hold	26,463	–	–	0.16%	103
2016 Q1	$3.8M	Hold	26,463	–	–	0.16%	98
2015 Q4	$5.69M	Buy	26,463 +12,000	+83%	+$2.19M	0.21%	87
2015 Q3	$2.34M	Hold	14,463	–	–	0.08%	140
2015 Q2	$3.73M	Hold	14,463	–	–	0.14%	94
2015 Q1	$3.25M	Buy	+14,463	New	+$3.02M	0.13%	93

Other funds holding AXDX

OIM

Oracle Investment Management Greenwich, Connecticut $168M AUM 42.86% 1-Year Est. Return

Birchview Capital Burlington, Vermont $214M AUM 185.33% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Cannell & Co New York $3.15B AUM 30.62% 1-Year Est. Return

William Blair & Company Chicago, Illinois $38.4B AUM 25.71% 1-Year Est. Return

ACH

ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return

NCGI

Next Century Growth Investors Plymouth, Minnesota $1.89B AUM 151.53% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Tekla Capital Management's AXDX Position: Q4 2017 in Review

Tekla Capital Management sold out of Accelerate Diagnostics (AXDX) in Q4 2017, closing a stake of 15,000 shares — an estimated $3.37M sold.

Tekla Capital Management first reported a position in AXDX in Q1 2015 and held it in 11 quarters. The position peaked at $5.69M in Q4 2015. 118 funds tracked by Wall St. Rank hold AXDX as of Q4 2017.

Tekla Capital Management reported no remaining Accelerate Diagnostics position as of Q4 2017 after selling out during the quarter.
Tekla Capital Management sold 15,000 Accelerate Diagnostics shares in Q4 2017, an estimated $3.37M.
Tekla Capital Management first reported a position in Accelerate Diagnostics in Q1 2015 and held it in 11 quarters.
Tekla Capital Management's Accelerate Diagnostics position peaked at $5.69M in Q4 2015.
118 funds tracked by Wall St. Rank held Accelerate Diagnostics as of Q4 2017.

Based on Tekla Capital Management's 13F filing for Q4 2017, filed 14 Feb 2018.